Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STP702
- Development stage
- Preclinical
- Lead developer
- Sirnaomics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intratumoral
01
Overview
STP702 is a small interfering RNA (siRNA) therapeutic designed to target and silence the expression of the spermidine/spermine N1-acetyltransferase 1 (SAT1 or SSAT1) gene. Developed by Sirnaomics, this drug utilizes their proprietary Polypeptide Nanoparticle (PNP) delivery technology. SAT1 is a key enzyme in polyamine catabolism, and its overexpression is linked to various cancers and the regulation of ferroptosis. By knocking down SAT1, STP702 aims to modulate polyamine metabolism and intracellular stress responses to inhibit tumor progression. It is primarily being investigated for the treatment of solid tumors, including glioblastoma.
- Other names
- spermidine/spermine n1-acetyltransferase 1-targeting small interfering RNASAT1 siRNASAT-1 siRNASAT 1 siRNASSAT1 siRNASSAT-1 siRNASSAT 1 siRNA
02
Targets
Flu (Influenza surface proteins)
Beyond the preview
Go deeper on STP702.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STP702.